Q-linea AB (publ) announced that Stuart Gander succeeds Jonas Jarvius as CEO. Stuart Gander brings extensive experience from leading positions in the global healthcare industry, with a focus on diagnostics and medical technologies. Through his management consulting background, he has supported companies on a range of operational challenges with a focus on driving sustainable change and growth, based on building strong and motivated teams. Stuart Gander is a Canadian citizen, has previously been working 15 years in Sweden, is currently living in the USA but will relocate to Sweden within the next 18 months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.27 SEK | -2.16% | -7.72% | -38.65% |
04-26 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
03-13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.65% | 24.47M | |
-42.18% | 2.85B | |
+22.02% | 1.94B | |
+0.39% | 1.68B | |
+27.15% | 1.26B | |
-10.70% | 1.03B | |
-18.27% | 938M | |
+0.66% | 783M | |
-25.07% | 628M | |
+14.62% | 535M |
- Stock Market
- Equities
- QLINEA Stock
- News Q-linea AB
- Q-linea AB Announces CEO Changes